ok?....

Buenas tardes ....

kes lo k a pasao ??

THQ Inc. (THQI)

-NasdaqGS

0.4501 Apr 17, 4:00PM EDT|Pre-Market: 0.66 0.2099 (+46.63%) 8:09AM EDT - Nasdaq Real Time Price






http://finance.yahoo.com/q?s=THQI&ql=0

http://www.google.com/finance?q=NASDAQ:THQI

resultados goods no?.... q borriqueria...

pos nada... yo soy de os que piensa... que si abre en un +40... vendo y a tomar por ssaco.... y que te quiten lo bailao ...


norawena si sta alguien dentro!

THQ Inc. (THQI) habia un anoticia mala ....de una semana >>>


THQ, mal su cotización, y mal sus proyectos de futuro. Si no encuentra socio, adiós al título Warhammer 40,000: Dark Millennium MMO.

http://www.zonapulp.com/videojuegos/...nnium-mmo.html

.... y sta de hoy >>>


THQ Inc. y Machinima han anunciado el lanzamiento inmediato de una beta pública de Nexuiz para PC, el arena shooter en primera persona desarrollado por IllFonic y potenciado por CryENGINE® 3


http://www.thq.com/es/go/article/vie...u_beta_para_pc

por cierto.... dos velitas muy muy chulis y apoyando en la MM200... las anticuillas PEIX.... yo no descartaria nada para ellas e....yo creo que podria intentar una entrada hoy.... para ver si mantiene...



aun tengo marcao en el pro los antiguos puntos a alcanzar..jejejeje... el ultimo lo tenia en 2.52..... ains... q apañao

depende de a como las tengas ..... se pue sabé ?? ... yo entre en 0.61.

gryphom.... como lo ves ??

http://www.marketwatch.com/story/thq...ons-2012-04-18

Preve buenas expectativas de ventas.

http://www.reuters.com/article/2012/...ySector&rpc=43

18 de abril (Reuters) - THQ Inc espera perder menos dinero en el cuarto trimestre de lo que había previsto anteriormente, ayudado por las fuertes ventas de sus servicios de video juegos de Saints Row: La Tercera y UFC Undisputed 3.

no.. si yo no tengo niguna thqi... pero digo.. q con aperturas de esas de gap tan gordo.. si tienes ganancias aunque sean pocas... yo siempre vendo....

y si no lee lo q te decia Gryphon hace un rato..... que no hay q tirar las ganancias echasss!..

Muchas gracias compañero. Gran foro éste, en el que apenas intervengo porque mis escasos conocimientos no dan para ello. Pero aprendo mucho de vosotros.

Un saludo y gracias a todos

Porque no cotiza IBCP ??

hoy que empezaba a trastear con el OTC.. y ahora las NEOM esas se ponen a to mecha... amos amos...

Si cotiza, o al menos eso veo yo..... lo que no tiene es casi nada de volumen....

Mientrasss toy d travelingg toy viendo q las clwr llevan una ostia d puta madre....juer....
Si sali bien salio si...oju...
Ale....pa ver si llego al hogar

Nuevas propiedades de la cerveza



http://www.consumer.es/seguridad-ali...3/28/22962.php

Arna vuelven a su sitio ??

http://www.google.com/finance?q=NASDAQ:ARNA

WENAS.. q llego ahora.. ofu q cansansio... por el amor del dos

toy mirando las alti... y aun no descarto otro pelotazo e... yo las sigo mirando... por si se arrancara ..

vamos.. aun tengo q echarle un ojo en el pro... a ver a ultima hora si los osos amorosos entran o no..

las biof se despeñan.. las clwr se despeñan...va tela..

ale.. tahora

Hacia minimos en 2,82 hace algunos años. Hoy ya la tenemos en 84 dolares y subiendo un 30%.

Catalyst Health Solutions, Inc. (CHSI)

http://es.finance.yahoo.com/q?s=CHSI

El medicamento para perder peso que presentaran este mes ante la FDA tiene todas las papeletas para ser rechazado.
Como lo aprueben............................ buuffffffffffffff.

y ese Volumen:22,166,780 ... es dinero entrando ?? ..pregunto.

http://finance.yahoo.com/q?s=ECDC&ql=1

que buena entrada en 45..hubiera sio ehhhhh!!!!...

otra vez high en 66...ese numerito tiene "magia"....

... como era eso de >>

....a wuenas horas mangas/verdes !!!!!

...pero me vale si se mantienen sta los 0.80


como las ves ??

La quiero comprar tan abajo que se me vuelve a escapar.

SinoTech Energy Limited (CTESY.PK)

http://es.finance.yahoo.com/q?s=CTESY.PK

ya te lo dije varias veces..hasta que no salgan los superventas..

suele ocurrir..como lo de querer vender muy ajustao y se te vuelven pabajo.....

esto es la reostia..me acabo de adquirir una tarjeta maroc telecom..y sale muy bien de precio..

y el adsl movil con el pincho...fijaros la capacidad de descarga...igualito que este territorio...

mejora a cualquier plan de expañistan...

Las cuotas mensuales de suscripción de dh / TTC:

Tipo de caudales * Precio
Internet 3G 3,6 Mb / s de datos de voz y datos sólo 3,6 Mb / s 99 TTC
Internet 3G 7,2 Mb / s de datos de voz y datos sólo 7,2 Mb / s 199 TTC


Marruecos de telecomunicaciones de doble ancho de banda gratuito a Internet 3G. Registrarse en la libertad de 99 dh / TTC.

* La velocidad de conexión depende del tope mensual. Una vez que el techo se alcanza la velocidad de Internet 3G va al final de cada mes a 512 Kb / s para un consumo de 5 GB, 256 Kb / s para un consumo de 10 GB, 128 Kb / s para un consumo de 15 GB y 64Kb / s para un consumo de 20 GB.

Ha saltado hace diez minutos. Estoy dentro.

Spherix Inc. (SPEX)

http://es.finance.yahoo.com/q?s=SPEX&ql=1

caya... q yo estoy del pincho hasta los

New Studies Conducted By Spherix Support Use Of D-Tagatose To Reduce And Stabilize Atherosclerotic Plaques



.PrintButton a {text-decoration:none;font-size:13px;padding:0 23px 0 0;height:20px;background:url('/common/images/icons/print.gif') right top no-repeat;}

.addnewsalertbutton a {height:20px;padding:0px 23px 4px 0;cursorointer; text-decoration:none;font-size:13px;background:url('http://uk.advfn.com/alerts/images/news_alerts_icon_small.png') right top no-repeat;}#article_body p{margin:0 0 15px 0;padding:0;max-width:800px}#article_body .articlechart p {width:360px;margin-top:10px} .articlechart {float:right;width:360px;margin:0 0 10px 20px} .articlechart h2{font-size:14px;text-align:center;margin:0;padding:0} .articlechart p {text-align:center;font-size:12px;padding:3px 0 10px 0;margin:0Spherix (NASDAQ:SPEX)
Intraday Stock Chart

Today : Wednesday 18 April 2012

Spherix Incorporated (NASDAQ: SPEX) - an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies - today announced results from its recently completed studies using near-infrared spectroscopy on autopsy samples from humans who had confirmed cardiovascular disease. Results showed that these atherosclerotic plaques had abnormally high amounts of macrophages and reduced levels of collagen and elastin. Reducing collagen and elastin weakens the plaques and contributes to plaque rupture, myocardial infarction and/or stroke (see photo).[1]
(Photo: http://photos.prnewswire.com/prnh/20120418/PH90198 )
Importantly, these findings show the relevance of Spherix's newly completed study involving D-tagatose and LDLR-/- mice, which are predisposed to developing atherosclerosis and mimic the pathogenesis of atherosclerosis in humans. Similar to what was found in the human study, infrared spectrometric imaging of diseased vascular samples from mice given an atherogenic diet containing high amounts of sucrose showed increases in macrophages and reductions in collagen and elastin content. The mice fed an atherogenic diet containing D-tagatose but not sucrose showed significantly fewer plaques and infrared spectrometric imaging of the plaques that developed revealed fewer macrophages, and more collagen and elastin. These results suggest that D-tagatose not only reduces the number of plaques formed, but also may stabilize atherosclerotic plaques.
LDL cholesterol particles imbedded within atherosclerotic plaques have been reported to attract circulating monocytes into the lesion, thereby leading to the accumulation of macrophages in the plaque and weakening of atherosclerotic lesions.[2] Diets high in fat, cholesterol and carbohydrates promote the development of atherosclerosis in both animals and humans by increasing triglycerides and LDL cholesterol in the blood. Dr. Robert Lodder, President of Spherix remarked, "We know that our drug candidate, SPX-106T, significantly reduces the number of atherosclerotic plaques in animal models. These new results, however, are very exciting because they not only support Spherix's previous findings, but also open the door to new therapeutic opportunities."
"It is encouraging to note that D-tagatose has a beneficial effect on atherosclerosis and Spherix is successfully providing experimental evidence that our two drug candidates in combination therapy, SPX-106T, work synergistically to produce the desired therapeutic activity needed to advance SPX-106T through clinical and regulatory development," said Dr. Claire Kruger, Spherix's Chief Executive Officer. "SPX-106T is consistent with our business strategy to develop combination drugs that affect multiple pathways to disease."
About SpherixSpherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries - Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis. Biospherics is exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke, and would like a pharmaceutical partner to continue development of D-tagatose as a treatment for diabetes. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. For more information, please visit www.spherix.com.
Forward-Looking StatementsThis release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of our products, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop products may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
[1]. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R, "Concept of vulnerable/unstable plaque," Arterioscler. Thromb. Vasc. Biol. 30 (7): 1282-92, July 2010.
[2]. Kreuzer J, Denger S, Jahn L, Bader J, Ritter K, von Hodenberg E, Kubler W, "LDL Stimulates Chemotaxis of Human Monocytes Through a Cyclooxygenase-Dependent Pathway, Arteriosclerosis, Thrombosis, and Vascular Biology," 16:1481-1487, 1996.
SOURCE Spherix Incorporated